Reopro

Roman name

ReoPro #

The composition and the form of

1 ml solution for injection contains abziksimaba (Fab-fragment chelovecesco-mashinh chimeric monoclonal antibody 7A3), 2 mg; in vials to 5 ml, in a carton.

Of drugs

Antitromboticescoe. Communicating with glikoproteinovmi receptor type IIb / IIIa (GPIIb / IIIa) human platelets, ingibiruet their agregatia, blocking tying fibrinoguena factor Villebranda etc. adgeziveh molecules with retseptorian site on activated platelets. Ingibiruet vitronektinove receptors (alfa_v, beta_3) and receptors Mac_1 monocytes and macrophages, which is posleactie drugs (reducing the risk of death by 60% over the next three years "EPIC" -study).

Pharmacokinetics

After the on / in the bolusni concentration in the plasma are falling rapidly (source T_1/2 less than 10 minutes, T_1/2 the second phase is about 30 minutes). In / in a dose of 0.25 mg / kg, followed by a continuous infuziei a 10 µ g / min is a constant concentration in plasma throughout infusions. After Infusion concentration of free drug plasma rapidly declining for about 6900 and then declines have been more slowly (in a blood-related trombozitami of up to 10 days).

Clinical pharmacology

In / in bolusnaya injection (0,15-0,3 mg / kg) led to rapid oppression ADF -induzirovanna aggregation of platelets. After 2 h after high doses (0.25 and 0.3 mg / kg) to hold more than 80% of receptor GPIIb / IIIa, with an average duration of bleeding increased at more than 30 minutes. The effect of gradually declining : Aggregation blood gills normal after 48 hours, the duration of bleeding-24 hrs (90% of patients).

Indications

Prevention of ischaemic complications in the heart in patients with high-risk groups who are at or angioplastike ateroektomii (as a further means to geparino and aspirin) : Drinking solace retidivirutaya Drinking or postinfarctnaya stenocardia, resistant to the drug therapy; Acute myocardial infarction with changes zubza Q within 12 hours after the start; angiograficski identified obstruction in the coronary circulation.

Pregnancy and lactation

When pregnancy only if clearly needed. In appointing lactating women should proceed with caution (it is better to suspend breastfeeding).

Contraindications

Hypersensitivity, active internal bleeding, recent (within 6 weeks) bleeding in the digestive tract or urinary system, the cerebral circulation (incl. history of the past two years or with significant residual neurological changes), bloody diates, receiving oral anticoagulants in the preceding seven days, thrombocytopenia (less than 100,000 cells / l) recent (within 6 weeks) extensive surgery or trauma, intracranial tumour, deformity arteries and veins or anevrizma, severe asthma hypertension, vasculit in history, in / with the introduction of dextran before coronary angioplasty, or to use them during coronary angioplastiki, child age (safety and efficacy have not been studied).

Side-Effects

Bleeding (in the arterial access for catheterization or internal bleeding in the digestive tract, urinary tract, retroperitonealnah plots), thrombocytopenia, allergic reactions (including anaphylacshiyu).

Patient interaction

Effect increase combined, and trombolitiki antitrombozitarnae drugs. Monoclonal antibodies imposed for the purpose of diagnosis and treatment, which increased the risk allergization.

Precautions

When profuzhnykh hemorrhage (uncontrolled AD), a severe allergic reaction or a trombozitopenia immediately cease and handling trombozitarnuu estate.

Dosing and Administration

In / in, 0.25 mg / kg bolusno (for 10-60 min before coronary angioplastiki), and then infuzionno, with a speed of 10 µ g / min for 12 h.

Storage conditions

r-r d / in. : List B.

Directory → Gematotropona funds → Antiagreganta → Reopro